New results suggest that the reference regimen should be neoadjuvant therapy with modified FOLFIRINOX (oxaliplatin 85 mg/m 2, irinotecan 180 mg/m 2, leucovorin 400 mg/m 2, and infusional 5 ...

The study outcomes, especially among the surgery cohort, stand in contrast to those observed in patients who receive the current standard neoadjuvant regimen for borderline resectable pancreatic ...

Novocure (NASDAQ:NVCR) has met the primary endpoint of overall survival in a late-stage trial evaluating the use of its Tumor Treating Fields (TTFields) therapy for pancreatic cancer. Shares of ...

Immunotherapy may boost KRAS-targeted therapy in pancreatic cancer. ScienceDaily. Retrieved July 12, 2025 from www.sciencedaily.com / releases / 2025 / 03 / 250314170603.htm.

Novocure (NVCR) achieves milestone in pancreatic cancer treatment with positive trial results for TTFields therapy, leading to a 25% surge in stock price.